• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

    3/25/25 5:15:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EXEL alert in real time by email

    – Presentations will highlight best- and/or first-in-class potential of four small molecule and biotherapeutic development candidates for investigation in patients with advanced solid tumors –

    Exelixis, Inc. (NASDAQ:EXEL) today announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 in Chicago, IL.

    "We are excited to share preclinical data from four of our pipeline molecules that constitute the next phase in our commitment to the discovery and development of innovative cancer treatments," said Dana T. Aftab, Ph.D., Executive Vice President, Discovery & Translational Research, and Chief Scientific Officer, Exelixis. "The results support the advancement into clinical development of these biotherapeutics and small molecules, as well as their potential to become best- and/or first-in-class therapies with differentiated clinical profiles."

    Exelixis will present preclinical data for XL495 and XL309, small molecules that have demonstrated synthetic lethality in the context of certain genetic anomalies frequently found in some tumors. Preclinical data will also be presented for the PD-L1xNKG2A-targeting bispecific antibody XB628 and the tissue factor-targeting antibody-drug conjugate XB371. Initial details about the poster presentations can be found below. Full data will be presented at the AACR Annual Meeting.

    Abstract 1733: XL495 is a potent, selective, and orally bioavailable inhibitor of PKMYT1

    Lead Author: Dana Gwinn, Ph.D.

    Session Title: Kinase and Phosphatase Inhibitors 1

    Monday, April 28, 2:00-5:00 p.m. CT

    Preclinical results will be presented for XL495, a novel, potent small molecule inhibitor of PKMYT1. The inhibition of PKMYT1 is synthetically lethal in cells with genetic anomalies that lead to replication stress—a common occurrence in cancer cells but not in normal cells. Data from the analysis show XL495 has demonstrated the potential for anti-tumor activity alone and in combination with DNA-damaging agents. A phase 1 clinical study of XL495 in patients with locally advanced or metastatic solid tumors, both as monotherapy and in combination with select cytotoxic agents in tumor-specific indications, is underway.

    Abstract 2936: Preclinical characterization of XB371, a novel anti-tissue factor antibody-drug conjugate

    Lead Author: Kathy Gogas, Ph.D.

    Session Title: Growth Factor Receptors and Other Surface Antigens as Targets for Therapy 1

    Monday, April 28, 2:00-5:00 p.m. CT

    This poster presentation will highlight preclinical data for XB371, an antibody-drug conjugate, constructed using Catalent's SMARTag® site-specific bioconjugation platform, that pairs a tissue factor-targeting antibody with a topoisomerase inhibitor payload using a novel cleavable linker. This design may offer the molecule broad applicability across tumor types and a clinically differentiated potential. Results to be presented support in vitro cell killing activity and in vivo efficacy, supporting the advancement of XB371 into clinical development. Exelixis is planning to submit an investigational new drug application to the U.S. Food and Drug Administration (FDA) for XB371 in 2025.

    Abstract 5723: XL309 is a potent, selective, and orally bioavailable USP1 inhibitor active as monotherapy and in combination with PARP inhibitors or irinotecan

    Lead Author: Alex Charruyer-Reinwald, Ph.D.

    Session Title: PARP Inhibitors

    Tuesday, April 29, 2:00-5:00 p.m. CT

    Preclinical results will be presented for XL309, a potent and selective small molecule inhibitor of USP1, the inhibition of which is lethal in cells with BRCA 1/2 mutations. The findings demonstrate activity of XL309 alone or in combination with PARP or topoisomerase inhibitors. A phase 1 clinical study of XL309 as a monotherapy or in combination with olaparib in patients with advanced solid tumors is underway.

    Abstract 6067: Preclinical evaluation of XB628: A novel PD-L1 x NKG2A bispecific antibody

    Lead Author: Bee-Cheng Sim, Ph.D.

    Session Title: Antibodies 3: Multi-Target Checkpoint Inhibitors and Immune Activators

    Tuesday, April 29, 2:00-5:00 p.m. CT

    Preclinical data on XB628, a first-in-class bispecific antibody that simultaneously targets PD-L1 and NKG2A, will be presented. Data from this analysis show that XB628 is efficacious in tumor cell killing in vitro and in vivo, supporting advancement of this molecule into clinical development. Earlier this month, the U.S. FDA cleared Exelixis' Investigational New Drug application for XB628.

    More information about Exelixis' pipeline is available at Exelixis.com.

    About Exelixis

    Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements, including, without limitation, statements related to: the presentation of positive preclinical data for advanced cancers at AACR 2025; the best- and/or first-in-class potential of small molecule and biotherapeutic development candidates for investigation in patients with advanced solid tumors; Exelixis' belief in the potential of these biotherapeutics and small molecules to become best- and/or first-in-class therapies with differentiated clinical profiles; Exelixis' plans to submit any investigational new drug applications to the FDA; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials; the costs of conducting clinical trials; Exelixis' ability to protect their respective intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption "Risk Factors" in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.

    Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis.

    SMARTag® is a registered trademark of Catalent Pharma Solutions, Inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250324794005/en/

    Investors Contact:

    Susan Hubbard

    EVP, Public Affairs and

    Investor Relations


    Exelixis, Inc.

    650-837-8194

    [email protected]

    Media Contact:

    Stekki Millman

    Senior Director, Public Affairs

    Exelixis, Inc.

    650-837-7187

    [email protected]

    Get the next $EXEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EXEL

    DatePrice TargetRatingAnalyst
    2/24/2025$36.00Overweight → Equal Weight
    Wells Fargo
    1/27/2025$30.00 → $40.00Equal-Weight → Overweight
    Morgan Stanley
    1/24/2025Outperform → Perform
    Oppenheimer
    12/20/2024$36.00 → $40.00Outperform → Market Perform
    BMO Capital Markets
    12/17/2024$35.00 → $39.00Buy → Neutral
    BofA Securities
    10/16/2024$30.00 → $34.00Outperform
    RBC Capital Mkts
    9/19/2024$30.00Neutral
    UBS
    4/11/2024$25.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $EXEL
    Financials

    Live finance-specific insights

    See more
    • Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

      - Total Revenues of $555.4 million, Cabozantinib Franchise U.S. Net Product Revenues of $513.3 million - - GAAP Diluted EPS of $0.55, Non-GAAP Diluted EPS of $0.62 - - Increasing 2025 Full Year Net Product Revenues and Total Revenues Guidance by $100 million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in CABOMETYX® d

      5/13/25 4:07:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

      – Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Event

      4/29/25 4:05:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

      - Total Revenues of $567 million for the Fourth Quarter of 2024, $2.17 billion for the Fiscal Year 2024 - - Cabozantinib Franchise Achieved $1.81 billion in U.S. Net Product Revenues for the Fiscal Year 2024, including $515 million for the Fourth Quarter of 2024 - - GAAP Diluted EPS of $0.48 for the Fourth Quarter of 2024, $1.76 for the Fiscal Year 2024 - - Non-GAAP Diluted EPS of $0.55 for the Fourth Quarter of 2024, $2.00 for the Fiscal Year 2024 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key corporate objectiv

      2/11/25 4:05:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    SEC Filings

    See more
    • SEC Form 144 filed by Exelixis Inc.

      144 - EXELIXIS, INC. (0000939767) (Subject)

      5/20/25 5:23:50 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Exelixis Inc.

      144 - EXELIXIS, INC. (0000939767) (Subject)

      5/15/25 4:05:42 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Exelixis Inc.

      10-Q - EXELIXIS, INC. (0000939767) (Filer)

      5/13/25 4:14:27 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

      – Zanzalintinib in combination with nivolumab demonstrated an objective response rate of 63% and a disease control rate of 90% – – Additional results from dose-finding cohorts will also be presented – Exelixis, Inc. (NASDAQ:EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either nivolumab (Opdivo®) or a fixed-dose combination of nivolumab and relatlimab (Opdualag™) in patients with previously untreated advanced clear cell renal cell carcinoma (RCC). These findings, as well as data from multiple dose-escalation cohorts from STELLAR-002, will be presented at the 2025 American Society of Clinical Oncology

      5/22/25 5:17:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

      - Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May and June: TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA: Exelixis is scheduled to present virtually at 2:30 p.m. ET / 11:30 a.m. PT on Tuesday, May 27. William Blair 45th Annual Growth Stock Conference: Exelixis is scheduled to present at 11:00 a.m. ET / 10:00 a.m. CT / 8:00 a.m. PT on Tuesday, June 3 in Chicago. Jefferies Global Healthcare Conference 2025: Exelixis is scheduled to present at 7:35 a.m. ET / 4:35 a.m. PT on Wednesday, June 4 in New York City.

      5/22/25 4:05:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

      Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, today announced that its collaboration partner, Exelixis, Inc. (NASDAQ:EXEL), has initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628 in participants with recurrent advanced or metastatic solid tumors. XB628 is a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1). The molecule was discovered in part through a collaboration between Exelixis and Invenra. About Invenra Inc. Invenra Inc. pioneers the discove

      5/13/25 6:06:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Leadership Updates

    Live Leadership Updates

    See more
    • ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

      TORONTO, Oct. 9, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE:AIAI) (OTCQB:AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, is pleased to announce the appointment of P.J. Haley, Executive Vice President, Commercial at Exelixis, Inc. (NASDAQ:EXEL), as a director of the Company, effective October 15th, 2024. Mr. Haley will be replacing Sheetal Jaitly, who is stepping down as a director after a period of dedicated service and contributions to the Company. As NetraMark focuses on advancing its technology for late phas

      10/9/24 8:30:00 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

      – Cabozantinib franchise achieves approximately $1.630 billion in preliminary U.S. net product revenues for fiscal year 2023 – – Fiscal year 2024 net product revenues guidance of $1,650 million - $1,750 million; 2024 R&D expense guidance of $925 million - $975 million – – Appointment of two new board members, Mary C. Beckerle, Ph.D., and Gail Eckhardt, M.D., with extensive drug development and corporate governance expertise – – Implementing corporate restructuring to focus R&D resources on clinical stage and IND-enabling activities to maximize pipeline success and operational efficiency – – Board of Directors authorized $450 million share repurchase in 2024 after successful completi

      1/7/24 4:00:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

      -- Dr. Peterson's extensive experience includes clinical development, medical affairs, and regulatory leadership in support of innovative oncology product portfolios -- Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed Amy Peterson, M.D., its next Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer. Dr. Peterson is a veteran oncology drug development leader whose experience includes senior clinical development and operational roles at Genentech, Medivation, BeiGene and CytomX. She joins Exelixis as the company accelerates development of its product pipeline and builds on the success of its global cabozantinib oncology franchise. "With a

      8/23/23 4:30:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for CABOMETYX issued to EXELIXIS INC

      Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-16) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/20/2023. Application Category: NDA, Application Number: 208692, Application Classification: Labeling

      9/21/23 4:37:02 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for CABOMETYX issued to EXELIXIS INC

      Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-14) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 07/14/2022. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

      7/15/22 4:38:40 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for CABOMETYX issued to EXELIXIS INC

      Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-12) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/17/2021. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

      9/20/21 3:53:29 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Beckerle Mary C was granted 9,812 shares, increasing direct ownership by 32% to 40,218 units (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      5/30/25 7:15:19 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Oliver Bob was granted 9,812 shares, increasing direct ownership by 29% to 43,326 units (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      5/30/25 7:14:58 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Heyman Tomas J. was granted 9,812 shares, increasing direct ownership by 30% to 42,282 units (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      5/30/25 7:14:31 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

      SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)

      5/8/24 4:11:20 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Exelixis Inc.

      SC 13G - EXELIXIS, INC. (0000939767) (Subject)

      2/13/24 9:19:48 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

      SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)

      6/2/23 5:05:24 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exelixis downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Exelixis from Overweight to Equal Weight and set a new price target of $36.00

      2/24/25 7:08:46 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Exelixis from Equal-Weight to Overweight and set a new price target of $40.00 from $30.00 previously

      1/27/25 7:40:23 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis downgraded by Oppenheimer

      Oppenheimer downgraded Exelixis from Outperform to Perform

      1/24/25 7:28:21 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Johnson David Edward bought $8,733,955 worth of shares (425,000 units at $20.55) (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      5/30/24 7:50:14 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Johnson David Edward bought $3,932,734 worth of shares (190,000 units at $20.70) (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      2/22/24 5:08:50 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Johnson David Edward sold $2,602,038 worth of shares (120,409 units at $21.61) and bought $2,602,038 worth of shares (120,409 units at $21.61) (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      11/29/23 4:30:29 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care